Drug Launch Marketing: The Media Plan From Pre-Launch to Year One

Launches are the most expensive and least forgiving period in a drug's commercial life. Early prescribing habits tend to stick, so the first months carry outsized weight. Yet the brand team is working with an unfinished label until the action date, a target list built on competitor behavior, and no historical performance data. Drug launch marketing is planning under that uncertainty.

The drug launch media plan in four phases

Pre-launch: shape the market without naming the drug

Before approval, the brand cannot promote the product. What it can usually do is unbranded disease awareness: content about the condition, its burden, diagnosis, and the importance of treatment, without naming or implying the product. For HCPs, this often means disease education, guideline awareness, and diagnostic testing education. The exact boundaries are a regulatory call for each piece.

Pre-launch is also when the operational work happens:

• Build the HCP target list from claims data on the condition and competitor prescribing. See how to build an NPI target list.
• Sign data, media, and measurement contracts so they are live by approval.
• Build the unbranded site and the branded site in parallel, with tags validated.
• Run small unbranded tests to learn which channels and audiences respond.
• Get Google certification for search if branded paid search is planned (see pharmaceutical PPC advertising).

For precision medicine launches, pre-launch often focuses on biomarker testing rates, because a drug that needs a positive test cannot be prescribed until patients are tested. The diagnostic data in precision medicine launches article covers that case.

Launch readiness: everything built, nothing live

The goal for the last three months is that approval day is a switch, not a project. Branded creative should be through MLR in near-final form based on the expected label, with a plan to update it within days if the final label differs. Campaigns should be built in each platform and paused. The NPI list should be matched and loaded. Holdout cells for measurement should be defined now, because they cannot be added cleanly after launch.

The first 90 days: concentrate, then watch

The first quarter is about getting the priority prescribers to know the drug exists, understand who it is for, and know how to get patients on it. That argues for concentrating budget on the top segments rather than spreading across the whole universe. Field and media should run off the same list. Access messaging matters a lot here, because early formulary coverage is often limited and physicians need to know what to expect.

Signals to watch weekly:

1. Reach against the priority NPI list, not just impressions.
2. HCP engagement on the professional site: dosing pages, access pages, sample or support requests.
3. Patient support program enrollments and their source.
4. Early new-to-brand prescription trend by segment and region, from syndicated data.
5. Branded search volume, as an indirect read on awareness.

Do not treat a weak first month as a verdict. Coverage delays and slow claims data can make early numbers look worse than the underlying trend.

Year one: reallocate on evidence, using gates set in advance

By months four to six, the first incremental readouts start to arrive. This is when the plan should change. Gates make that easier, because the team agreed in advance what results lead to which decision.

The scale, hold, or stop framework is a good template for writing these gates.

What usually goes wrong at launch

• The gap between approval and first impression. Weeks lost to unsigned IOs, unfinished MLR, or a missing certification.
• No holdout. Every launch brand wants to know what worked. Without a control group set up before launch, the answer is a guess.
• DTC before access. Patients ask for a drug their plan does not yet cover, and the experience turns them and their doctors off.
• Launch plan frozen for the year. The plan built on assumptions never gets revisited when data arrives.

The general campaign steps still apply; launches just run them on a longer clock. See pharmaceutical campaign planning for the step sequence and pharmaceutical marketing strategies for the framework the launch plan should sit inside.

Practical takeaway

If you are within a year of an action date, write down the number of days between approval and the first branded impression your current plan allows. Then list every dependency on that path: MLR, IOs, list matching, certification, tags. Any dependency without an owner and a date is where launch week will slip.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.